Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment
| Autor: | Xuemin WANG, Weihong ZHANG, Weijiao DU, Xinwei ZHANG, Xiubao REN, Shui CAO |
|---|---|
| Jazyk: | čínština |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Chinese Journal of Lung Cancer, Vol 20, Iss 11, Pp 761-768 (2017) |
| Druh dokumentu: | article |
| ISSN: | 1009-3419 1999-6187 |
| DOI: | 10.3779/j.issn.1009-3419.2017.11.07 |
| Popis: | Background and objective The efficacy of second or third-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is low. The use of targeted drugs brings survival benefit for some patients. Apatinib, as a novel small molecule antiangiogenic drug, has demonstrated satisfactory anticancer activity across a broad range of malignancies. The aim of this study is to evaluate the efficacy and safety of apatinib in patients with advanced NSCLC after first-line treatment failure. Methods A retrospective study of 128 patients was conducted to evaluate the safety, short-term efficacy and survival status with different regimens. Kaplan-Meier method and Cox regression model were used for analysis. Results Compared with chemotherapy alone, the median progression free survival (PFS) in apatinib monotherapy, chemotherapy alone and apatinib combined with chemotherapy were 3.0 (P=0.381), 3.7 and 6.0 months (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|